Valtrex herpes transmission indication
Executive Summary
GlaxoSmithKline's Valtrex (valacyclovir) clears FDA for reduction of the risk of heterosexual transmission of genital herpes when used as a suppressive therapy in combination with safer sex practices. The approval follows the recommendations of the Antiviral Drugs Advisory Committee during a May 14 meeting (1"The Pink Sheet" May 19, 2003, p. 14)...
You may also be interested in...
GSK’s Valtrex Clears FDA Cmte.; Herpes Transmission Endpoints Debated
Clinical studies for genital herpes drugs intended to demonstrate a reduction in disease transmission should include seroconversion as a primary endpoint, FDA's Antiviral Drugs Advisory Committee agreed May 14
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.